Study of adebrelimab and apatinib before surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests giving a combination of two medications, adebrelimab (an immunotherapy) and apatinib (a targeted therapy), before surgery for people with stage II or III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your cancer is stage II, IIIA, or select stage IIIB non-small cell lung cancer (squamous or non-squamous type).
- You have not had any prior cancer treatment, and your doctor believes surgery can completely remove the cancer.
- Your tumor tests positive for PD-L1 (a protein that helps the immune system attack cancer) at a level of 1% or more.
- Your overall health is good enough for surgery, with normal liver, kidney, and blood function.
- You do not have certain genetic changes (EGFR or ALK) if your cancer is non-squamous.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests whether adding new immunotherapy drugs (adebrelimab or retlirafusp alfa plus recaticimab) to standard chemotherapy before lung surgery can help people with resectable non-small cell lung cancer. The goal is to see if this combination improves outcomes for patients whose tumors can be surgically removed.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
This trial tests two medicines given before lung cancer surgery: benmelstobart (an immunotherapy that helps your immune system fight cancer) and anlotinib (a targeted therapy that stops blood vessel growth to tumors). The goal is to see if they make the cancer disappear completely by the time of surgery.
This study tests a drug called adebrelimab, used alone or with other treatments, for people with advanced solid tumors, including extensive-stage small cell lung cancer. It aims to see if adding this drug helps control the cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.